Twenty-two percent of U.S. doctors prescribing initial treatment for children with a new diagnosis of anxiety or depression during a recent six-year period chose medications that are not federally approved for use in children or were inconsistent with guidelines issued by professional associations, exposing patients to a greater risk of bad outcomes, according to a new Yale study.
This article was originally published on MedicalXpress.com

